Firefly BioWorks, Inc., a Cambridge, MA-based developer of next-generation multiplexed assays for biomarker detection, has received a $500k grant from the Massachusetts Life Sciences Center.
The award was granted through the Center’s Small Business Matching Grant Program, which was created to accelerate the commercialization of new products for companies that have already received Phase II Small Business Innovation Research (SBIR) funding from federal agencies such as the National Institutes of Health.
The company intends to use these funds to expand the reach of its products to clinical scientists and research hospitals.
Led by co-founder and CEO Davide Marini, Ph.D., and -founder and CTO Daniel Pregibon, Ph.D., Firefly BioWorks is introducing a high-performance, universal technology platform for multiplexed biomarker detection, with applications in life sciences research and clinical diagnostics. Assays can be performed on standard laboratory equipment, such as flow cytometers, microarray scanners and fluorescence microscopes.
FirePlex(TM), the company’s first product, is designed to detect microRNAs.
FinSMEs
24/05/2012